World News – GB – Exeter coronavirus vaccine: BCG given to 1,000 people on trial


Posted: 12:58 PM EDT October 10, 2020 | Updated: 5:54 p.m. EDT October 10, 2020

A vaccine usually given to protect children from tuburcolosis could help adults fight coronavirus, researchers at the University of Exeter say

The Bacillus Calmette – Guérin (BCG) vaccine will be recruited from 1,000 people after the vaccine has been found to stimulate the immune system

It would not be the ultimate solution, but rather help people fight the coronavirus until more effective vaccines are discovered

Professor John Campbell of the University of Exeter School of Medicine told The Guardian the vaccine could ‘be a game changer on a global scale’

Bacillus Calmette – Guérin (BCG) vaccine will be recruited from 1,000 people after vaccine found to boost immune system Pictured are people wearing masks in Newcastle

The University of Exeter to recruit 2,000 UK community health workers for the international Brace trial – which is recruiting 10,000 volunteers worldwide

Trial volunteers will either receive an injection of BCG or a placebo They will then be monitored for a year to see if the vaccinated group has fewer Covid-19 infections or has fewer symptoms

The University of Exeter will recruit 2,000 UK community health workers for the international Brace trial – which is recruiting 10,000 volunteers worldwide (file image)

BCG typically elicits an immune response against bacterial TB disease – but is now believed to help protect against viral infections

The Bacillus Calmette-Guérin (BCG) vaccine is only given to people who are thought to be at increased risk of coming into contact with tuberculosis (TB)

BCG vaccination is recommended for babies up to 1 year old who are born in areas of the UK where tuberculosis rates are higher than in the rest of the country, including parts of central London, or who have a parent or grandparent who was born in a country with a high TB ​​rate

BCG vaccination may also be recommended for older children who are at increased risk of developing tuberculosis, such as children recently arrived from countries with high tuberculosis rates or who have been in close contact with it. a person infected with respiratory tuberculosis

BCG vaccination is rarely given to people over 16 because it does not work very well in adults

But it is given to adults aged 16 to 35 who are at risk of tuberculosis because of their work, such as some health workers

Although it was once administered to high school children, it was replaced in 2005 by a targeted program for babies, children and young adults at higher risk of tuberculosis

Last month’s trial results published in the journal Cell suggest older people have fewer respiratory infections after receiving the vaccine, according to work by an international team of scientists

«  If we see anything close to this kind of protection for the coronavirus, it could be a game-changer for the world,  » Campbell said

The vaccine is designed to stimulate the adaptive immune system which can then release antibodies to destroy invading tuberculosis pathogens

But it also boosts the body’s ‘innate’ immune system, which means infections can be fought off before they have a chance to set in. It is this effect that has given scientists hope that it could work as a vaccine against the coronavirus

If it turns out to protect against viral infections, the vaccine could be deployed in future pandemics

Mihia Netea, a researcher at Radboud University in the Netherlands, said: «  We believe that in an unvaccinated person the virus enters and begins to multiply, but the host’s defenses are slow, so the virus has a chance multiply a lot ‘

If the infected person had received the BCG vaccine, however, the trial seeks to prove that it would boost the immune system’s response and prevent the virus from multiplying so quickly

The trial comes after it was revealed that Covid-19 jabs are expected to be offered by the NHS as early as next month, with five mass vaccination centers expected to be in action by Christmas

Leaked provisional documents revealed a plan to deploy hundreds of NHS workers to five locations across the country – injecting tens of thousands of people every day, The Sun reported

The most vulnerable to the coronavirus will be called in first, with centers manned by nurses in training and paramedics scheduled in Leeds, Hull and London, the publication reports

In addition to the five large-scale static sites, GPs and pharmacists will be invited to participate in the mass vaccination effort, with a fleet of mobile units to be used to reach vulnerable communities and those in homes. of care

A source told The Sun: ‘The earliest possible time to get the first results from the trial is in a month – which means the best case scenario for a potential deployment is right before Christmas

‘But the planning is well underway, so there will be no delay in vaccination once we have a working jab’

Nursing home residents and staff will be the first to receive a Covid-19 vaccine when it is approved, according to new government advice

All people over 80 and NHS staff will be in second place, according to updated guidance from the States Joint Committee on Immunization and Immunization

The body, which consists of 20 top scientists, advises ministers on all vaccines It has admitted its directions for any UK vaccination program against Covid-19 are likely to change in the future

Matt Hancock had previously promised that Brits with underlying conditions would be near the front of the queue for any shotBut millions of people living with heart disease or other illnesses that increase their risk of dying from Covid-19 will not be vaccinated until all people over 65 are vaccinated, according to new guidelines

According to the classification proposed by the Joint Committee on Vaccination and Immunization, the vaccines will be deployed in the following order:

Tentative plans say month’s end is the vaccine launch date, but without UK regulators and European Medicines Agency approval to administer the vaccination, the schedule is unlikely to remain stable

The Health Secretary told the Conservatives’ virtual conference that ‘plans are underway’ to combine the NHS and the military to ‘roll out’

He said people will get the vaccine « according to priority » – but did not specify what that order would be

The main candidate in the race to find a vaccine is the University of Oxford, where trials have been underway since April – it is hoped that the vaccine could be approved by regulators by Christmas

Around 100 million doses of the Oxford vaccination, which has not yet been proven to be successful, have already been ordered by the government

The vaccines developed by the University of Oxford require two inoculations, 28 days apart, which means the logistical challenge facing the government is twofold

Giving two doses of a vaccine to 53 million adults during the six-month period would involve 600,000 injections per day

The proposals, leaked to The Sun, also suggested that health workers, including vets, dieticians and chiropodists, could also help administer doses to the public if regulations are relaxed to allow it.

Those who need the injections most are first on the list, which means residents and nursing home staff will receive them as soon as they are ready

People over 80 and NHS staff are next, followed by all over 65, higher risk young adults, and people over 50

On Monday, the head of the national vaccine task force, Kate Bingham, said less than half of Britain would get vaccinated against Covid-19

She said ministers hope around 30 million people will receive the potentially life-threatening blow, out of a total of nearly 67 million

Ms Bingham said: ‘We just need to vaccinate everyone at risk’, revealing that no one under 18 will get a dose

A Royal Society report last week warned that the distribution and production of the vaccine on such a scale would present significant challenges

Nilay Shah, head of the chemical engineering department at Imperial College London and co-author of the report, said: ‘Even when the vaccine is available it doesn’t mean that in a month everyone will be vaccinated

An investigation into the University of Oxford’s potential coronavirus vaccine is set to miss a crucial part of the test – as a US regulator has suspended the process to investigate side effects

Trial participants should be given a booster shot, but this cannot happen while the US investigation is ongoing

This could mean that the results of volunteers in the United States testing the vaccine cannot be used to evaluate treatment

At least 30,000 participants in the United States had started testing the drug by the end of August, but the process was halted when a person in Britain suffered side effects

This means that the American volunteers will not be able to get their second booster injection after 28 days, putting the test at risk

Eleanor Riley, professor of immunology at the University of Edinburgh, told The Times: « There is ample evidence to indicate that a longer interval is actually better

« However, changing the interval in the middle of a trial can be problematic Anyone who does not get vaccinated according to the given schedule should be excluded from the final analysis of the trial

« This means they may need to recruit additional people to make up the numbers This will obviously add more delay to getting a response

« If a large group is affected by the delay, they can still analyze their data, as a secondary subgroup analysis, to see if the difference in timing is having an effect »

‘We’re talking about six months, nine months a year There is no question of life suddenly returning to normal in March’

Yesterday, WHO Director-General Tedros Adhanom Ghebreyesus revealed that he expected a vaccine against COVID-19 could be ready by the end of the year

Dr Ghebreyesus said in his closing remarks to the WHO Executive Board, without giving details: “We will need vaccines and there is hope that by the end of this year we will can have a vaccine There is hope ‘

Nine experimental vaccines are in preparation for the WHO COVAX global vaccination facility, which aims to distribute 2 billion doses by the end of 2021

Britain is currently bound by the European Medicines Agency until January, meaning it cannot administer the drug even if it is approved by UK regulators

The Ministry of Health said: ‘We are confident that we have the adequate supply or transport, PPE and logistical expertise to deploy a Covid-19 vaccine as quickly as possible through the country’

Several challenges were highlighted in the Royal Society report, including the need to inject people with RNA, a type of genetic material, in some of the most promising studies, even though a vaccine to RNA has never been produced on a large scale

Questions also remain about supply chains, with some vaccines having to be stored at -80 ° C during transport

In addition, up to 80% of the population may need to be inoculated to achieve herd immunity, even if a vaccine is 90% effective in reducing transmission

Another contender in the race to vaccinate the world is New York-based Codagenix, which plans to begin experiments with its vaccine in London by the end of the year

The vaccine will be of a type called a live attenuated vaccine, which means people will receive a genetically modified version of the coronavirus that is weaker than reality but still infectious

Live attenuated vaccines – such as the MMR vaccine – work by stimulating the immune system in the same way as the real Covid-19, but relying on viruses incapable of causing serious illness

Codagenix says its vaccine has been successful after a single dose in animal trials and is designed to produce immunity against various parts of the coronavirus, rather than just the «  spike protein  » on the outside that many others concentrated

This could mean it would still work even if the virus were to mutate Using a live virus can allow doctors to create a type of immunity similar to what the body would do naturally

For now, the UK is now well and truly in the middle of a second wave, with 6,000 new cases every day and hospital admissions doubling every week

Share what you think

The opinions expressed in the above content are those of our users and do not necessarily reflect the views of MailOnline

We will automatically post your comment and a link to the story on your Facebook timeline at the same time it is posted on MailOnline To do this, we will link your MailOnline account to your Facebook account We will ask you to confirm it for your first message on Facebook

You can choose on each post if you want it to be posted on Facebook Your Facebook details will be used to provide you with personalized content, marketing and advertising in accordance with our privacy policy

Vaccine, BCG vaccine, Coronavirus, University of Exeter, Tuberculosis

News from the world – GB – Exeter coronavirus vaccine: BCG is administered to 1000 people in trial


Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: